ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Plasma lipid metabolites as biomarkers of early white matter degeneration in Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma complex lipids in relation to cortical thickness and brain volumes: results from the population-based Rhineland study.Lipids in health and disease · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
Abstract
introductionAlzheimer's disease (AD) is characterized by progressive white matter (WM) degeneration. Circulating lipid metabolites may serve as early indicators of WM microstructural changes. In this study, we investigated the associations between plasma lipid metabolites and WM integrity across the cognitive continuum.
methodsWe included 173 participants from the Alzheimer's Disease Neuroimaging Initiative (51 cognitively normal [CN], 88 mild cognitive impairment [MCI], 34 AD) database. Plasma metabolites were quantified using targeted lipidomics, and diffusion tensor imaging (DTI) metrics were derived from 52 predefined WM regions.
resultsRegression analyses revealed widespread metabolite-DTI associations in MCI, particularly within the corpus callosum. The callosal body and splenium showed significant inverse associations with phosphatidylcholines (PCs) and multiple lysophosphatidylcholines (lysoPCs) species. In AD group, inverse relationships between PCs and the internal capsule were observed. DISCUSSION: Circulating lipid metabolites are linked to WM microstructure in both prodromal and clinical AD, supporting their potential as sensitive biomarkers of early vulnerability and disease progression. Highlights: Circulating lipid metabolites link to white matter integrity in early Alzheimer's disease (AD)Phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), and propionylcarnitine associate with tract-specific diffusion magnetic resonance imaging (dMRI) metricsNo metabolite-white matter associations detected in established ADPlasma metabolites may serve as biomarkers of early white matter degeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.